07:06 AM EDT, 09/16/2024 (MT Newswires) -- Pfizer ( PFE ) said Saturday that longer-term follow-up results from the phase 2 single-arm PHAROS clinical trial evaluating BRAFTOVI in combination with MEKTOVI show clinically meaningful response in patients with non-small cell lung cancer.

The objective response rate and the median duration of response were 75% and 40 months in treatment-naive patients and 46% and 16.7 months in previously treated patients, respectively, as assessed by an independent radiology review after an additional 18 months of follow-up.

Moreover, the median progression-free survival with BRAFTOVI and MEKTOVI was 30.2 months after about three years of follow-up in treatment-naive patients, the company said.

Price: 29.41, Change: +0.14, Percent Change: +0.48